QIAGEN partners with Clinical Genomics to monitor patients for recurrence of colorectal cancer.
M2 EQUITYBITES-August 22, 2017-QIAGEN partners with Clinical Genomics to monitor patients for recurrence of colorectal cancer
(C)2017 M2 COMMUNICATIONS http://www.m2.com
QIAGEN (NASDAQ:QGEN) (Frankfurt Prime Standard:QIA) on Monday reported the launch of an agreement to provide testing as well as monitor the recurrence of colorectal cancer patients, as conveniently as possible, in partnership with Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer.
Under the partnership, QIAGEN has implemented the PAXgeneBlood ccfDNA Tube sample collection in Clinical Genomics' Colvera colorectal cancer (CRC) recurrence assay.
According to the companies, Colvera is an integrated liquid biopsy solution that is designed to enable easy and accurate monitoring for recurrence of colorectal cancer with a simple blood test collected in a physician's office. PAXgene allows a simple blood collection at the physician's office, with no on-site processing required.
The convenient blood test uses novel technology to test for recurrence of tumors by detecting circulating DNA that may indicate recurrence of a cancer, concluded the companies.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Aug 22, 2017|
|Previous Article:||Donaldson names Jacquie Boyer as new VP of global OEM sales.|
|Next Article:||BIOTRONIK unveils Edora HF-T QP MR CRT-P therapy pacemaker in the US.|